{"transactions":[{"id":14267,"issuer":{"id":2794,"kind":"organization","name":"ELI LILLY & Co","symbol":"LLY"},"owners":[{"id":11096,"kind":"person","name":"Van Naarden Jacob","position":1,"cik":"0001661254","reported_name":"Van Naarden Jacob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP,Pres LLY Oncology&HdCorpBD"}}],"security":"Common Stock","published_at":"2026-02-11T21:25:13.000Z","date":"2026-02-09","kind":"grant","planned":false,"acquired":true,"shares":4865.888,"price":1044.67,"value":5083247.21696,"ownership":{"direct":true},"balance_after":26626.498,"source":{"system":"sec-edgar","filing":"0001661254-26-000004","document":"wk-form4_1770845109.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/59478/000166125426000004/wk-form4_1770845109.xml","form_type":"4"}},{"id":14767,"issuer":{"id":2794,"kind":"organization","name":"ELI LILLY & Co","symbol":"LLY"},"owners":[{"id":11096,"kind":"person","name":"Van Naarden Jacob","position":1,"cik":"0001661254","reported_name":"Van Naarden Jacob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP,Pres LLY Oncology&HdCorpBD"}}],"security":"Restricted Stock Unit","published_at":"2026-02-03T21:31:00.000Z","date":"2026-02-01","kind":"exercise","planned":false,"acquired":false,"shares":4108,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock."}],"balance_after":0,"derivative":{"exercise_date":"2026-02-01","expiration_date":"2026-02-01","underlying":"Common Stock","underlying_shares":4108},"source":{"system":"sec-edgar","filing":"0001661254-26-000002","document":"wk-form4_1770154258.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/59478/000166125426000002/wk-form4_1770154258.xml","form_type":"4"}},{"id":14766,"issuer":{"id":2794,"kind":"organization","name":"ELI LILLY & Co","symbol":"LLY"},"owners":[{"id":11096,"kind":"person","name":"Van Naarden Jacob","position":1,"cik":"0001661254","reported_name":"Van Naarden Jacob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP,Pres LLY Oncology&HdCorpBD"}}],"security":"Common Stock","published_at":"2026-02-03T21:31:00.000Z","date":"2026-02-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":1909.375,"price":1037.15,"value":1980308.28125,"ownership":{"direct":true},"balance_after":22760.61,"source":{"system":"sec-edgar","filing":"0001661254-26-000002","document":"wk-form4_1770154258.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/59478/000166125426000002/wk-form4_1770154258.xml","form_type":"4"}},{"id":14765,"issuer":{"id":2794,"kind":"organization","name":"ELI LILLY & Co","symbol":"LLY"},"owners":[{"id":11096,"kind":"person","name":"Van Naarden Jacob","position":1,"cik":"0001661254","reported_name":"Van Naarden Jacob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP,Pres LLY Oncology&HdCorpBD"}}],"security":"Common Stock","published_at":"2026-02-03T21:31:00.000Z","date":"2026-02-01","kind":"exercise","planned":false,"acquired":true,"shares":4108,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":24669.985,"source":{"system":"sec-edgar","filing":"0001661254-26-000002","document":"wk-form4_1770154258.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/59478/000166125426000002/wk-form4_1770154258.xml","form_type":"4"}},{"id":20891,"issuer":{"id":2794,"kind":"organization","name":"ELI LILLY & Co","symbol":"LLY"},"owners":[{"id":11096,"kind":"person","name":"Van Naarden Jacob","position":1,"cik":"0001661254","reported_name":"Van Naarden Jacob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Pres., Lilly Oncology"}}],"security":"Common Stock","published_at":"2025-08-13T20:15:45.000Z","date":"2025-08-13","kind":"purchase","planned":false,"acquired":true,"shares":1000,"price":647.36,"value":647360.0,"ownership":{"direct":true},"balance_after":20561.985,"source":{"system":"sec-edgar","filing":"0000059478-25-000218","document":"wk-form4_1755116139.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/59478/000005947825000218/wk-form4_1755116139.xml","form_type":"4"}},{"id":28404,"issuer":{"id":2794,"kind":"organization","name":"ELI LILLY & Co","symbol":"LLY"},"owners":[{"id":11096,"kind":"person","name":"Van Naarden Jacob","position":1,"cik":"0001661254","reported_name":"Van Naarden Jacob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Pres., Lilly Oncology"}}],"security":"Restricted Stock Unit","published_at":"2025-02-12T21:28:10.000Z","date":"2025-02-10","kind":"grant","planned":false,"acquired":true,"shares":4108,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock."}],"balance_after":4108,"derivative":{"exercise_date":"2026-02-01","expiration_date":"2026-02-01","underlying":"Common Stock","underlying_shares":4108},"source":{"system":"sec-edgar","filing":"0000059478-25-000057","document":"wk-form4_1739395681.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/59478/000005947825000057/wk-form4_1739395681.xml","form_type":"4"}},{"id":28403,"issuer":{"id":2794,"kind":"organization","name":"ELI LILLY & Co","symbol":"LLY"},"owners":[{"id":11096,"kind":"person","name":"Van Naarden Jacob","position":1,"cik":"0001661254","reported_name":"Van Naarden Jacob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Pres., Lilly Oncology"}}],"security":"Common Stock","published_at":"2025-02-12T21:28:10.000Z","date":"2025-02-10","kind":"grant","planned":false,"acquired":true,"shares":6103.824,"price":868.88,"value":5303490.59712,"ownership":{"direct":true},"balance_after":19561.985,"source":{"system":"sec-edgar","filing":"0000059478-25-000057","document":"wk-form4_1739395681.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/59478/000005947825000057/wk-form4_1739395681.xml","form_type":"4"}},{"id":29222,"issuer":{"id":2794,"kind":"organization","name":"ELI LILLY & Co","symbol":"LLY"},"owners":[{"id":11096,"kind":"person","name":"Van Naarden Jacob","position":1,"cik":"0001661254","reported_name":"Van Naarden Jacob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Pres., Lilly Oncology"}}],"security":"Restricted Stock Unit","published_at":"2025-02-04T21:26:23.000Z","date":"2025-02-01","kind":"exercise","planned":false,"acquired":false,"shares":3023,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock."}],"balance_after":0,"derivative":{"exercise_date":"2025-02-01","expiration_date":"2025-02-01","underlying":"Common Stock","underlying_shares":3023},"source":{"system":"sec-edgar","filing":"0000059478-25-000030","document":"wk-form4_1738704376.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/59478/000005947825000030/wk-form4_1738704376.xml","form_type":"4"}},{"id":29221,"issuer":{"id":2794,"kind":"organization","name":"ELI LILLY & Co","symbol":"LLY"},"owners":[{"id":11096,"kind":"person","name":"Van Naarden Jacob","position":1,"cik":"0001661254","reported_name":"Van Naarden Jacob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Pres., Lilly Oncology"}}],"security":"Common Stock","published_at":"2025-02-04T21:26:23.000Z","date":"2025-02-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":1409.839,"price":811.08,"value":1143492.21612,"ownership":{"direct":true},"balance_after":13458.161,"source":{"system":"sec-edgar","filing":"0000059478-25-000030","document":"wk-form4_1738704376.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/59478/000005947825000030/wk-form4_1738704376.xml","form_type":"4"}},{"id":29220,"issuer":{"id":2794,"kind":"organization","name":"ELI LILLY & Co","symbol":"LLY"},"owners":[{"id":11096,"kind":"person","name":"Van Naarden Jacob","position":1,"cik":"0001661254","reported_name":"Van Naarden Jacob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Pres., Lilly Oncology"}}],"security":"Common Stock","published_at":"2025-02-04T21:26:23.000Z","date":"2025-02-01","kind":"exercise","planned":false,"acquired":true,"shares":3023,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":14868,"source":{"system":"sec-edgar","filing":"0000059478-25-000030","document":"wk-form4_1738704376.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/59478/000005947825000030/wk-form4_1738704376.xml","form_type":"4"}},{"id":34373,"issuer":{"id":2794,"kind":"organization","name":"ELI LILLY & Co","symbol":"LLY"},"owners":[{"id":11096,"kind":"person","name":"Van Naarden Jacob","position":1,"cik":"0001661254","reported_name":"Van Naarden Jacob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Pres., Lilly Oncology"}}],"security":"Common Stock","published_at":"2024-11-01T20:17:41.000Z","date":"2024-10-31","kind":"gift","planned":false,"acquired":false,"shares":4302,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reporting person transferred 4,302 shares of Eli Lilly and Company common stock to the reporting person's spouse."}],"balance_after":11845,"source":{"system":"sec-edgar","filing":"0000059478-24-000247","document":"wk-form4_1730492255.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/59478/000005947824000247/wk-form4_1730492255.xml","form_type":"4"}},{"id":46460,"issuer":{"id":2794,"kind":"organization","name":"ELI LILLY & Co","symbol":"LLY"},"owners":[{"id":11096,"kind":"person","name":"Van Naarden Jacob","position":1,"cik":"0001661254","reported_name":"Van Naarden Jacob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Pres., Loxo@Lilly"}}],"security":"Restricted Stock Unit","published_at":"2024-02-14T21:41:27.000Z","date":"2024-02-12","kind":"grant","planned":false,"acquired":true,"shares":3023,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock."}],"balance_after":3023,"derivative":{"exercise_date":"2025-02-01","expiration_date":"2025-02-01","underlying":"Common Stock","underlying_shares":3023},"source":{"system":"sec-edgar","filing":"0000059478-24-000058","document":"wk-form4_1707946860.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/59478/000005947824000058/wk-form4_1707946860.xml","form_type":"4"}},{"id":46459,"issuer":{"id":2794,"kind":"organization","name":"ELI LILLY & Co","symbol":"LLY"},"owners":[{"id":11096,"kind":"person","name":"Van Naarden Jacob","position":1,"cik":"0001661254","reported_name":"Van Naarden Jacob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Pres., Loxo@Lilly"}}],"security":"Common Stock","published_at":"2024-02-14T21:41:27.000Z","date":"2024-02-12","kind":"grant","planned":false,"acquired":true,"shares":2369,"price":737.26,"value":1746568.94,"ownership":{"direct":true},"balance_after":16147,"source":{"system":"sec-edgar","filing":"0000059478-24-000058","document":"wk-form4_1707946860.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/59478/000005947824000058/wk-form4_1707946860.xml","form_type":"4"}},{"id":47661,"issuer":{"id":2794,"kind":"organization","name":"ELI LILLY & Co","symbol":"LLY"},"owners":[{"id":11096,"kind":"person","name":"Van Naarden Jacob","position":1,"cik":"0001661254","reported_name":"Van Naarden Jacob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Pres., Loxo@Lilly"}}],"security":"Restricted Stock Unit","published_at":"2024-02-02T21:22:59.000Z","date":"2024-02-01","kind":"exercise","planned":false,"acquired":false,"shares":3618,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock."}],"balance_after":0,"derivative":{"exercise_date":"2024-02-01","expiration_date":"2024-02-01","underlying":"Common Stock","underlying_shares":3618},"source":{"system":"sec-edgar","filing":"0000059478-24-000015","document":"wk-form4_1706908964.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/59478/000005947824000015/wk-form4_1706908964.xml","form_type":"4"}},{"id":47660,"issuer":{"id":2794,"kind":"organization","name":"ELI LILLY & Co","symbol":"LLY"},"owners":[{"id":11096,"kind":"person","name":"Van Naarden Jacob","position":1,"cik":"0001661254","reported_name":"Van Naarden Jacob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Pres., Loxo@Lilly"}}],"security":"Common Stock","published_at":"2024-02-02T21:22:59.000Z","date":"2024-02-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":1685,"price":645.61,"value":1087852.85,"ownership":{"direct":true},"balance_after":13778,"source":{"system":"sec-edgar","filing":"0000059478-24-000015","document":"wk-form4_1706908964.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/59478/000005947824000015/wk-form4_1706908964.xml","form_type":"4"}},{"id":47659,"issuer":{"id":2794,"kind":"organization","name":"ELI LILLY & Co","symbol":"LLY"},"owners":[{"id":11096,"kind":"person","name":"Van Naarden Jacob","position":1,"cik":"0001661254","reported_name":"Van Naarden Jacob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Pres., Loxo@Lilly"}}],"security":"Common Stock","published_at":"2024-02-02T21:22:59.000Z","date":"2024-02-01","kind":"exercise","planned":false,"acquired":true,"shares":3618,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":15463,"source":{"system":"sec-edgar","filing":"0000059478-24-000015","document":"wk-form4_1706908964.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/59478/000005947824000015/wk-form4_1706908964.xml","form_type":"4"}},{"id":58551,"issuer":{"id":2794,"kind":"organization","name":"ELI LILLY & Co","symbol":"LLY"},"owners":[{"id":11096,"kind":"person","name":"Van Naarden Jacob","position":1,"cik":"0001661254","reported_name":"Van Naarden Jacob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and CEO Loxo@Lilly"}}],"security":"Restricted Stock Unit","published_at":"2023-02-21T21:35:46.000Z","date":"2023-02-16","kind":"exercise","acquired":false,"shares":2785,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock."}],"balance_after":0,"derivative":{"exercise_date":"2023-02-16","expiration_date":"2023-02-16","underlying":"Common Stock","underlying_shares":2785},"source":{"system":"sec-edgar","filing":"0000059478-23-000079","document":"wf-form4_167701530938901.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/59478/000005947823000079/wf-form4_167701530938901.xml","form_type":"4"}},{"id":58550,"issuer":{"id":2794,"kind":"organization","name":"ELI LILLY & Co","symbol":"LLY"},"owners":[{"id":11096,"kind":"person","name":"Van Naarden Jacob","position":1,"cik":"0001661254","reported_name":"Van Naarden Jacob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and CEO Loxo@Lilly"}}],"security":"Common Stock","published_at":"2023-02-21T21:35:46.000Z","date":"2023-02-16","kind":"tax_withholding","acquired":false,"shares":1314,"price":335.01,"value":440203.14,"ownership":{"direct":true},"balance_after":11845,"source":{"system":"sec-edgar","filing":"0000059478-23-000079","document":"wf-form4_167701530938901.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/59478/000005947823000079/wf-form4_167701530938901.xml","form_type":"4"}},{"id":58549,"issuer":{"id":2794,"kind":"organization","name":"ELI LILLY & Co","symbol":"LLY"},"owners":[{"id":11096,"kind":"person","name":"Van Naarden Jacob","position":1,"cik":"0001661254","reported_name":"Van Naarden Jacob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and CEO Loxo@Lilly"}}],"security":"Common Stock","published_at":"2023-02-21T21:35:46.000Z","date":"2023-02-16","kind":"exercise","acquired":true,"shares":2785,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":13159,"source":{"system":"sec-edgar","filing":"0000059478-23-000079","document":"wf-form4_167701530938901.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/59478/000005947823000079/wf-form4_167701530938901.xml","form_type":"4"}},{"id":59130,"issuer":{"id":2794,"kind":"organization","name":"ELI LILLY & Co","symbol":"LLY"},"owners":[{"id":11096,"kind":"person","name":"Van Naarden Jacob","position":1,"cik":"0001661254","reported_name":"Van Naarden Jacob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and CEO Loxo@Lilly"}}],"security":"Common Stock","published_at":"2023-02-14T22:07:38.000Z","date":"2023-02-10","kind":"grant","acquired":true,"shares":2407,"price":345.12,"value":830703.84,"ownership":{"direct":true},"balance_after":10374,"source":{"system":"sec-edgar","filing":"0000059478-23-000065","document":"wf-form4_167641243711205.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/59478/000005947823000065/wf-form4_167641243711205.xml","form_type":"4"}},{"id":70766,"issuer":{"id":2794,"kind":"organization","name":"ELI LILLY & Co","symbol":"LLY"},"owners":[{"id":11096,"kind":"person","name":"Van Naarden Jacob","position":1,"cik":"0001661254","reported_name":"Van Naarden Jacob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CEO LoxoONC, Pres LlyONC"}}],"security":"Restricted Stock Unit","published_at":"2022-02-17T21:44:49.000Z","date":"2022-02-16","kind":"exercise","acquired":false,"shares":5461,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock."}],"balance_after":0,"derivative":{"exercise_date":"2022-02-16","expiration_date":"2022-02-16","underlying":"Common Stock","underlying_shares":5461},"source":{"system":"sec-edgar","filing":"0000059478-22-000065","document":"wf-form4_164513426243246.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/59478/000005947822000065/wf-form4_164513426243246.xml","form_type":"4"}},{"id":70765,"issuer":{"id":2794,"kind":"organization","name":"ELI LILLY & Co","symbol":"LLY"},"owners":[{"id":11096,"kind":"person","name":"Van Naarden Jacob","position":1,"cik":"0001661254","reported_name":"Van Naarden Jacob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CEO LoxoONC, Pres LlyONC"}}],"security":"Common Stock","published_at":"2022-02-17T21:44:49.000Z","date":"2022-02-16","kind":"tax_withholding","acquired":false,"shares":2186,"price":243.84,"value":533034.24,"ownership":{"direct":true},"balance_after":7967,"source":{"system":"sec-edgar","filing":"0000059478-22-000065","document":"wf-form4_164513426243246.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/59478/000005947822000065/wf-form4_164513426243246.xml","form_type":"4"}},{"id":70764,"issuer":{"id":2794,"kind":"organization","name":"ELI LILLY & Co","symbol":"LLY"},"owners":[{"id":11096,"kind":"person","name":"Van Naarden Jacob","position":1,"cik":"0001661254","reported_name":"Van Naarden Jacob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CEO LoxoONC, Pres LlyONC"}}],"security":"Common Stock","published_at":"2022-02-17T21:44:49.000Z","date":"2022-02-16","kind":"exercise","acquired":true,"shares":5461,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":10153,"source":{"system":"sec-edgar","filing":"0000059478-22-000065","document":"wf-form4_164513426243246.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/59478/000005947822000065/wf-form4_164513426243246.xml","form_type":"4"}},{"id":73708,"issuer":{"id":2794,"kind":"organization","name":"ELI LILLY & Co","symbol":"LLY"},"owners":[{"id":11096,"kind":"person","name":"Van Naarden Jacob","position":1,"cik":"0001661254","reported_name":"Van Naarden Jacob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CEO LoxoONC, Pres LlyONC"}}],"security":"Restricted Stock Unit","published_at":"2021-12-30T21:09:44.000Z","date":"2021-12-28","kind":"grant","acquired":true,"shares":3618,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units vest on February 1, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units vest on February 1, 2024."}],"balance_after":3618,"derivative":{"underlying":"Common Stock","underlying_shares":3618},"source":{"system":"sec-edgar","filing":"0000059478-21-000248","document":"wf-form4_164089857090230.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/59478/000005947821000248/wf-form4_164089857090230.xml","form_type":"4"}},{"id":3653166,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":11096,"kind":"person","name":"Van Naarden Jacob","position":1,"cik":"0001661254","reported_name":"Van Naarden Jacob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2019-02-15T09:18:43.000Z","date":"2019-02-15","kind":"disposition_to_issuer","acquired":false,"shares":57000,"price":235,"value":13395000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation (\"Lilly\"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly (\"Merger Sub\"), and Loxo Oncology, Inc., a Delaware corporation (\"Loxo Oncology\"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the \"Merger\"). Pursuant to the Merger Agreement each issued and outstanding shares (the \"Shares\") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":139.77,"expiration_date":"2029-01-01","underlying":"Common Stock","underlying_shares":57000},"source":{"system":"sec-edgar","filing":"0001567619-19-004576","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1581720/000156761919004576/doc1.xml","form_type":"4"}},{"id":3653165,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":11096,"kind":"person","name":"Van Naarden Jacob","position":1,"cik":"0001661254","reported_name":"Van Naarden Jacob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2019-02-15T09:18:43.000Z","date":"2019-02-15","kind":"disposition_to_issuer","acquired":false,"shares":200000,"price":235,"value":47000000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation (\"Lilly\"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly (\"Merger Sub\"), and Loxo Oncology, Inc., a Delaware corporation (\"Loxo Oncology\"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the \"Merger\"). Pursuant to the Merger Agreement each issued and outstanding shares (the \"Shares\") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":84.88,"expiration_date":"2028-01-03","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001567619-19-004576","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1581720/000156761919004576/doc1.xml","form_type":"4"}},{"id":3653164,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":11096,"kind":"person","name":"Van Naarden Jacob","position":1,"cik":"0001661254","reported_name":"Van Naarden Jacob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2019-02-15T09:18:43.000Z","date":"2019-02-15","kind":"disposition_to_issuer","acquired":false,"shares":35000,"price":235,"value":8225000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation (\"Lilly\"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly (\"Merger Sub\"), and Loxo Oncology, Inc., a Delaware corporation (\"Loxo Oncology\"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the \"Merger\"). Pursuant to the Merger Agreement each issued and outstanding shares (the \"Shares\") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":43.56,"expiration_date":"2027-03-14","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001567619-19-004576","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1581720/000156761919004576/doc1.xml","form_type":"4"}},{"id":3653163,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":11096,"kind":"person","name":"Van Naarden Jacob","position":1,"cik":"0001661254","reported_name":"Van Naarden Jacob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2019-02-15T09:18:43.000Z","date":"2019-02-15","kind":"disposition_to_issuer","acquired":false,"shares":74000,"price":235,"value":17390000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation (\"Lilly\"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly (\"Merger Sub\"), and Loxo Oncology, Inc., a Delaware corporation (\"Loxo Oncology\"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the \"Merger\"). Pursuant to the Merger Agreement each issued and outstanding shares (the \"Shares\") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":26.27,"expiration_date":"2026-12-05","underlying":"Common Stock","underlying_shares":74000},"source":{"system":"sec-edgar","filing":"0001567619-19-004576","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1581720/000156761919004576/doc1.xml","form_type":"4"}},{"id":3653162,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":11096,"kind":"person","name":"Van Naarden Jacob","position":1,"cik":"0001661254","reported_name":"Van Naarden Jacob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2019-02-15T09:18:43.000Z","date":"2019-02-15","kind":"disposition_to_issuer","acquired":false,"shares":43000,"price":235,"value":10105000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation (\"Lilly\"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly (\"Merger Sub\"), and Loxo Oncology, Inc., a Delaware corporation (\"Loxo Oncology\"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the \"Merger\"). Pursuant to the Merger Agreement each issued and outstanding shares (the \"Shares\") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":31.69,"expiration_date":"2025-12-15","underlying":"Common Stock","underlying_shares":43000},"source":{"system":"sec-edgar","filing":"0001567619-19-004576","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1581720/000156761919004576/doc1.xml","form_type":"4"}},{"id":3653161,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":11096,"kind":"person","name":"Van Naarden Jacob","position":1,"cik":"0001661254","reported_name":"Van Naarden Jacob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2019-02-15T09:18:43.000Z","date":"2019-02-15","kind":"disposition_to_issuer","acquired":false,"shares":78943,"price":235,"value":18551605.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation (\"Lilly\"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly (\"Merger Sub\"), and Loxo Oncology, Inc., a Delaware corporation (\"Loxo Oncology\"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the \"Merger\"). Pursuant to the Merger Agreement each issued and outstanding shares (the \"Shares\") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":13.67,"expiration_date":"2024-12-18","underlying":"Common Stock","underlying_shares":78943},"source":{"system":"sec-edgar","filing":"0001567619-19-004576","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1581720/000156761919004576/doc1.xml","form_type":"4"}},{"id":3653160,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":11096,"kind":"person","name":"Van Naarden Jacob","position":1,"cik":"0001661254","reported_name":"Van Naarden Jacob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2019-02-15T09:18:43.000Z","date":"2019-02-15","kind":"disposition_to_issuer","acquired":false,"shares":35026,"price":235,"value":8231110.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation (\"Lilly\"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly (\"Merger Sub\"), and Loxo Oncology, Inc., a Delaware corporation (\"Loxo Oncology\"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the \"Merger\"). Pursuant to the Merger Agreement each issued and outstanding shares (the \"Shares\") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":3.648,"expiration_date":"2024-06-18","underlying":"Common Stock","underlying_shares":35026},"source":{"system":"sec-edgar","filing":"0001567619-19-004576","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1581720/000156761919004576/doc1.xml","form_type":"4"}},{"id":3653159,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":11096,"kind":"person","name":"Van Naarden Jacob","position":1,"cik":"0001661254","reported_name":"Van Naarden Jacob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2019-02-15T09:18:43.000Z","date":"2019-02-15","kind":"disposition_to_issuer","acquired":false,"shares":19000,"price":235,"value":4465000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation (\"Lilly\"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly (\"Merger Sub\"), and Loxo Oncology, Inc., a Delaware corporation (\"Loxo Oncology\"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the \"Merger\"). Pursuant to the Merger Agreement each issued and outstanding shares (the \"Shares\") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation (\"Lilly\"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly (\"Merger Sub\"), and Loxo Oncology, Inc., a Delaware corporation (\"Loxo Oncology\"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the \"Merger\"). Pursuant to the Merger Agreement each issued and outstanding shares (the \"Shares\") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to withholding taxes."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001567619-19-004576","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1581720/000156761919004576/doc1.xml","form_type":"4"}},{"id":3692552,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":11096,"kind":"person","name":"Van Naarden Jacob","position":1,"cik":"0001661254","reported_name":"Van Naarden Jacob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2019-01-17T08:08:38.000Z","date":"2018-07-09","kind":"exercise","acquired":true,"shares":1541,"price":3.648,"value":5621.568,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"This amended Form 4 is being filed solely to correct the reporting person's ending balance by subtracting the additional 1,700 shares of the Issuer's common stock (the \"Additional Shares\") that were added inadvertently to the total number of shares held directly by the reporting person. The Additional Shares were included in all the subsequent transactions in the Form 4 filed on July 11, 2018 and the five Forms 4 filed thereafter. As of January 17, 2019, the reporting person directly holds a total number of 19,000 shares of the Issuer's common stock."}],"balance_after":13541,"source":{"system":"sec-edgar","filing":"0001567619-19-001262","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1581720/000156761919001262/doc1.xml","form_type":"4/A","original_submission_date":"2018-07-11"}},{"id":3712614,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":11096,"kind":"person","name":"Van Naarden Jacob","position":1,"cik":"0001661254","reported_name":"Van Naarden Jacob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2019-01-02T17:04:42.000Z","date":"2019-01-02","kind":"grant","acquired":true,"shares":57000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable as to 1/48th of the total number of shares on February 2, 2019, then an additional 1/48th vests on each monthly anniversary thereafter,until such time as the option is 100% vested,  subject to the reporting person's continued service through each vesting date."}],"balance_after":57000,"derivative":{"exercise_price":139.77,"expiration_date":"2029-01-01","underlying":"Common Stock","underlying_shares":57000},"source":{"system":"sec-edgar","filing":"0001567619-19-000102","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1581720/000156761919000102/doc1.xml","form_type":"4"}},{"id":3733681,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":11096,"kind":"person","name":"Van Naarden Jacob","position":1,"cik":"0001661254","reported_name":"Van Naarden Jacob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2018-12-12T17:17:25.000Z","date":"2018-12-11","kind":"exercise","acquired":false,"shares":7000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F16","text":"The stock option vested and became exercisable as to 25% of the shares subject to the option on May 12, 2015, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date."}],"balance_after":33326,"derivative":{"exercise_price":3.648,"expiration_date":"2024-06-18","underlying":"Common Stock","underlying_shares":7000},"source":{"system":"sec-edgar","filing":"0001567619-18-007788","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1581720/000156761918007788/doc1.xml","form_type":"4"}},{"id":3733680,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":11096,"kind":"person","name":"Van Naarden Jacob","position":1,"cik":"0001661254","reported_name":"Van Naarden Jacob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2018-12-12T17:17:25.000Z","date":"2018-12-11","kind":"exercise","acquired":false,"shares":4500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F15","text":"The stock option vests and becomes exercisable in 48 equal monthly installments beginning on January 19, 2015, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date."}],"balance_after":78943,"derivative":{"exercise_price":13.67,"expiration_date":"2024-12-18","underlying":"Common Stock","underlying_shares":4500},"source":{"system":"sec-edgar","filing":"0001567619-18-007788","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1581720/000156761918007788/doc1.xml","form_type":"4"}},{"id":3733679,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":11096,"kind":"person","name":"Van Naarden Jacob","position":1,"cik":"0001661254","reported_name":"Van Naarden Jacob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2018-12-12T17:17:25.000Z","date":"2018-12-10","kind":"exercise","acquired":false,"shares":4500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F15","text":"The stock option vests and becomes exercisable in 48 equal monthly installments beginning on January 19, 2015, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date."}],"balance_after":83443,"derivative":{"exercise_price":13.67,"expiration_date":"2024-12-18","underlying":"Common Stock","underlying_shares":4500},"source":{"system":"sec-edgar","filing":"0001567619-18-007788","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1581720/000156761918007788/doc1.xml","form_type":"4"}},{"id":3733678,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":11096,"kind":"person","name":"Van Naarden Jacob","position":1,"cik":"0001661254","reported_name":"Van Naarden Jacob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2018-12-12T17:17:25.000Z","date":"2018-12-11","kind":"exercise","acquired":true,"shares":7000,"price":3.648,"value":25536.0,"ownership":{"direct":true},"balance_after":20700,"source":{"system":"sec-edgar","filing":"0001567619-18-007788","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1581720/000156761918007788/doc1.xml","form_type":"4"}},{"id":3733677,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":11096,"kind":"person","name":"Van Naarden Jacob","position":1,"cik":"0001661254","reported_name":"Van Naarden Jacob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2018-12-12T17:17:25.000Z","date":"2018-12-11","kind":"sale","acquired":false,"shares":541,"price":140.16,"value":75826.56,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the aggregate of sales effected on the same day at different prices."},{"field":"price","element":"transactionPricePerShare","label":"F14","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $139.75 to $140.54 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":13700,"source":{"system":"sec-edgar","filing":"0001567619-18-007788","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1581720/000156761918007788/doc1.xml","form_type":"4"}},{"id":3733676,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":11096,"kind":"person","name":"Van Naarden Jacob","position":1,"cik":"0001661254","reported_name":"Van Naarden Jacob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2018-12-12T17:17:25.000Z","date":"2018-12-11","kind":"sale","acquired":false,"shares":500,"price":139.23,"value":69615.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the aggregate of sales effected on the same day at different prices."},{"field":"price","element":"transactionPricePerShare","label":"F13","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $138.64 to $139.60 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":14241,"source":{"system":"sec-edgar","filing":"0001567619-18-007788","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1581720/000156761918007788/doc1.xml","form_type":"4"}},{"id":3733675,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":11096,"kind":"person","name":"Van Naarden Jacob","position":1,"cik":"0001661254","reported_name":"Van Naarden Jacob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2018-12-12T17:17:25.000Z","date":"2018-12-11","kind":"sale","acquired":false,"shares":500,"price":137.73,"value":68865.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the aggregate of sales effected on the same day at different prices."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $137.49 to $137.93 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":14741,"source":{"system":"sec-edgar","filing":"0001567619-18-007788","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1581720/000156761918007788/doc1.xml","form_type":"4"}},{"id":3733674,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":11096,"kind":"person","name":"Van Naarden Jacob","position":1,"cik":"0001661254","reported_name":"Van Naarden Jacob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2018-12-12T17:17:25.000Z","date":"2018-12-11","kind":"sale","acquired":false,"shares":1759,"price":137.09,"value":241141.31,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the aggregate of sales effected on the same day at different prices."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $136.45 to $137.43 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":15241,"source":{"system":"sec-edgar","filing":"0001567619-18-007788","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1581720/000156761918007788/doc1.xml","form_type":"4"}},{"id":3733673,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":11096,"kind":"person","name":"Van Naarden Jacob","position":1,"cik":"0001661254","reported_name":"Van Naarden Jacob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2018-12-12T17:17:25.000Z","date":"2018-12-11","kind":"sale","acquired":false,"shares":800,"price":135.92,"value":108736.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the aggregate of sales effected on the same day at different prices."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $135.44 to $136.42 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":17000,"source":{"system":"sec-edgar","filing":"0001567619-18-007788","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1581720/000156761918007788/doc1.xml","form_type":"4"}},{"id":3733672,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":11096,"kind":"person","name":"Van Naarden Jacob","position":1,"cik":"0001661254","reported_name":"Van Naarden Jacob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2018-12-12T17:17:25.000Z","date":"2018-12-11","kind":"sale","acquired":false,"shares":400,"price":134.74,"value":53896.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the aggregate of sales effected on the same day at different prices."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $134.39 to $135.33 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":17800,"source":{"system":"sec-edgar","filing":"0001567619-18-007788","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1581720/000156761918007788/doc1.xml","form_type":"4"}},{"id":3733671,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":11096,"kind":"person","name":"Van Naarden Jacob","position":1,"cik":"0001661254","reported_name":"Van Naarden Jacob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2018-12-12T17:17:25.000Z","date":"2018-12-11","kind":"exercise","acquired":true,"shares":4500,"price":13.67,"value":61515.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."}],"balance_after":18200,"source":{"system":"sec-edgar","filing":"0001567619-18-007788","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1581720/000156761918007788/doc1.xml","form_type":"4"}},{"id":3733670,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":11096,"kind":"person","name":"Van Naarden Jacob","position":1,"cik":"0001661254","reported_name":"Van Naarden Jacob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2018-12-12T17:17:25.000Z","date":"2018-12-10","kind":"sale","acquired":false,"shares":100,"price":137.39,"value":13739.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."}],"balance_after":13700,"source":{"system":"sec-edgar","filing":"0001567619-18-007788","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1581720/000156761918007788/doc1.xml","form_type":"4"}},{"id":3733669,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":11096,"kind":"person","name":"Van Naarden Jacob","position":1,"cik":"0001661254","reported_name":"Van Naarden Jacob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2018-12-12T17:17:25.000Z","date":"2018-12-10","kind":"sale","acquired":false,"shares":200,"price":136.48,"value":27296.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the aggregate of sales effected on the same day at different prices."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $136.09 to $136.86 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":13800,"source":{"system":"sec-edgar","filing":"0001567619-18-007788","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1581720/000156761918007788/doc1.xml","form_type":"4"}},{"id":3733668,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":11096,"kind":"person","name":"Van Naarden Jacob","position":1,"cik":"0001661254","reported_name":"Van Naarden Jacob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2018-12-12T17:17:25.000Z","date":"2018-12-10","kind":"sale","acquired":false,"shares":500,"price":135.14,"value":67570.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the aggregate of sales effected on the same day at different prices."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $135.06 to $135.21 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":14000,"source":{"system":"sec-edgar","filing":"0001567619-18-007788","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1581720/000156761918007788/doc1.xml","form_type":"4"}},{"id":3733667,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":11096,"kind":"person","name":"Van Naarden Jacob","position":1,"cik":"0001661254","reported_name":"Van Naarden Jacob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2018-12-12T17:17:25.000Z","date":"2018-12-10","kind":"sale","acquired":false,"shares":1400,"price":134.65,"value":188510.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the aggregate of sales effected on the same day at different prices."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $134.06 to $134.96 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":14500,"source":{"system":"sec-edgar","filing":"0001567619-18-007788","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1581720/000156761918007788/doc1.xml","form_type":"4"}},{"id":3733666,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":11096,"kind":"person","name":"Van Naarden Jacob","position":1,"cik":"0001661254","reported_name":"Van Naarden Jacob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2018-12-12T17:17:25.000Z","date":"2018-12-10","kind":"sale","acquired":false,"shares":900,"price":133.17,"value":119853.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the aggregate of sales effected on the same day at different prices."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $132.66 to $133.54 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":15900,"source":{"system":"sec-edgar","filing":"0001567619-18-007788","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1581720/000156761918007788/doc1.xml","form_type":"4"}},{"id":3733665,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":11096,"kind":"person","name":"Van Naarden Jacob","position":1,"cik":"0001661254","reported_name":"Van Naarden Jacob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2018-12-12T17:17:25.000Z","date":"2018-12-10","kind":"sale","acquired":false,"shares":1000,"price":132.23,"value":132230.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the aggregate of sales effected on the same day at different prices."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $131.63 to $132.39 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":16800,"source":{"system":"sec-edgar","filing":"0001567619-18-007788","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1581720/000156761918007788/doc1.xml","form_type":"4"}},{"id":3733664,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":11096,"kind":"person","name":"Van Naarden Jacob","position":1,"cik":"0001661254","reported_name":"Van Naarden Jacob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2018-12-12T17:17:25.000Z","date":"2018-12-10","kind":"sale","acquired":false,"shares":400,"price":130.59,"value":52236.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the aggregate of sales effected on the same day at different prices."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $130.37 to $130.79 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":17800,"source":{"system":"sec-edgar","filing":"0001567619-18-007788","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1581720/000156761918007788/doc1.xml","form_type":"4"}},{"id":3733663,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":11096,"kind":"person","name":"Van Naarden Jacob","position":1,"cik":"0001661254","reported_name":"Van Naarden Jacob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2018-12-12T17:17:25.000Z","date":"2018-12-10","kind":"exercise","acquired":true,"shares":4500,"price":13.67,"value":61515.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."}],"balance_after":18200,"source":{"system":"sec-edgar","filing":"0001567619-18-007788","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1581720/000156761918007788/doc1.xml","form_type":"4"}},{"id":3750036,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":11096,"kind":"person","name":"Van Naarden Jacob","position":1,"cik":"0001661254","reported_name":"Van Naarden Jacob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2018-11-28T17:13:30.000Z","date":"2018-11-27","kind":"exercise","acquired":false,"shares":2057,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F16","text":"The stock option vests and becomes exercisable in 48 equal monthly installments beginning on January 19, 2015, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date."}],"balance_after":87943,"derivative":{"exercise_price":13.67,"expiration_date":"2024-12-18","underlying":"Common Stock","underlying_shares":2057},"source":{"system":"sec-edgar","filing":"0001567619-18-007050","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":22,"url":"https://www.sec.gov/Archives/edgar/data/1581720/000156761918007050/doc1.xml","form_type":"4"}},{"id":3750035,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":11096,"kind":"person","name":"Van Naarden Jacob","position":1,"cik":"0001661254","reported_name":"Van Naarden Jacob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2018-11-28T17:13:30.000Z","date":"2018-11-27","kind":"exercise","acquired":false,"shares":2443,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F15","text":"The stock option vested and became exercisable as to 25% of the shares subject to the option on May 12, 2015, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date."}],"balance_after":40326,"derivative":{"exercise_price":3.648,"expiration_date":"2024-06-18","underlying":"Common Stock","underlying_shares":2443},"source":{"system":"sec-edgar","filing":"0001567619-18-007050","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/1581720/000156761918007050/doc1.xml","form_type":"4"}},{"id":3750034,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":11096,"kind":"person","name":"Van Naarden Jacob","position":1,"cik":"0001661254","reported_name":"Van Naarden Jacob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2018-11-28T17:13:30.000Z","date":"2018-11-26","kind":"exercise","acquired":false,"shares":5500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F15","text":"The stock option vested and became exercisable as to 25% of the shares subject to the option on May 12, 2015, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date."}],"balance_after":42769,"derivative":{"exercise_price":3.648,"expiration_date":"2024-06-18","underlying":"Common Stock","underlying_shares":5500},"source":{"system":"sec-edgar","filing":"0001567619-18-007050","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/1581720/000156761918007050/doc1.xml","form_type":"4"}},{"id":3750033,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":11096,"kind":"person","name":"Van Naarden Jacob","position":1,"cik":"0001661254","reported_name":"Van Naarden Jacob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2018-11-28T17:13:30.000Z","date":"2018-11-27","kind":"sale","acquired":false,"shares":200,"price":151.55,"value":30310.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."}],"balance_after":13700,"source":{"system":"sec-edgar","filing":"0001567619-18-007050","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1581720/000156761918007050/doc1.xml","form_type":"4"}},{"id":3750032,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":11096,"kind":"person","name":"Van Naarden Jacob","position":1,"cik":"0001661254","reported_name":"Van Naarden Jacob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2018-11-28T17:13:30.000Z","date":"2018-11-27","kind":"sale","acquired":false,"shares":200,"price":149.46,"value":29892.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the aggregate of sales effected on the same day at different prices."},{"field":"price","element":"transactionPricePerShare","label":"F14","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $149.21 to $149.71 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":13900,"source":{"system":"sec-edgar","filing":"0001567619-18-007050","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1581720/000156761918007050/doc1.xml","form_type":"4"}},{"id":3750031,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":11096,"kind":"person","name":"Van Naarden Jacob","position":1,"cik":"0001661254","reported_name":"Van Naarden Jacob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2018-11-28T17:13:30.000Z","date":"2018-11-27","kind":"sale","acquired":false,"shares":81,"price":147.99,"value":11987.19,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."}],"balance_after":14100,"source":{"system":"sec-edgar","filing":"0001567619-18-007050","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1581720/000156761918007050/doc1.xml","form_type":"4"}},{"id":3750030,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":11096,"kind":"person","name":"Van Naarden Jacob","position":1,"cik":"0001661254","reported_name":"Van Naarden Jacob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2018-11-28T17:13:30.000Z","date":"2018-11-27","kind":"sale","acquired":false,"shares":300,"price":147.06,"value":44118.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the aggregate of sales effected on the same day at different prices."},{"field":"price","element":"transactionPricePerShare","label":"F13","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $146.99 to $147.10 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":14181,"source":{"system":"sec-edgar","filing":"0001567619-18-007050","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1581720/000156761918007050/doc1.xml","form_type":"4"}},{"id":3750029,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":11096,"kind":"person","name":"Van Naarden Jacob","position":1,"cik":"0001661254","reported_name":"Van Naarden Jacob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2018-11-28T17:13:30.000Z","date":"2018-11-27","kind":"sale","acquired":false,"shares":100,"price":144.97,"value":14497.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."}],"balance_after":14481,"source":{"system":"sec-edgar","filing":"0001567619-18-007050","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1581720/000156761918007050/doc1.xml","form_type":"4"}},{"id":3750028,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":11096,"kind":"person","name":"Van Naarden Jacob","position":1,"cik":"0001661254","reported_name":"Van Naarden Jacob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2018-11-28T17:13:30.000Z","date":"2018-11-27","kind":"sale","acquired":false,"shares":200,"price":143.92,"value":28784.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the aggregate of sales effected on the same day at different prices."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $143.69 to $144.14 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":14581,"source":{"system":"sec-edgar","filing":"0001567619-18-007050","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1581720/000156761918007050/doc1.xml","form_type":"4"}},{"id":3750027,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":11096,"kind":"person","name":"Van Naarden Jacob","position":1,"cik":"0001661254","reported_name":"Van Naarden Jacob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2018-11-28T17:13:30.000Z","date":"2018-11-27","kind":"sale","acquired":false,"shares":500,"price":143.08,"value":71540.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the aggregate of sales effected on the same day at different prices."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $142.64 to $143.27 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":14781,"source":{"system":"sec-edgar","filing":"0001567619-18-007050","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1581720/000156761918007050/doc1.xml","form_type":"4"}},{"id":3750026,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":11096,"kind":"person","name":"Van Naarden Jacob","position":1,"cik":"0001661254","reported_name":"Van Naarden Jacob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2018-11-28T17:13:30.000Z","date":"2018-11-27","kind":"sale","acquired":false,"shares":500,"price":141.69,"value":70845.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the aggregate of sales effected on the same day at different prices."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $141.39 to $142.00 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":15281,"source":{"system":"sec-edgar","filing":"0001567619-18-007050","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1581720/000156761918007050/doc1.xml","form_type":"4"}},{"id":3750025,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":11096,"kind":"person","name":"Van Naarden Jacob","position":1,"cik":"0001661254","reported_name":"Van Naarden Jacob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2018-11-28T17:13:30.000Z","date":"2018-11-27","kind":"sale","acquired":false,"shares":300,"price":140.13,"value":42039.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the aggregate of sales effected on the same day at different prices."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $140.08 to $140.23 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":15781,"source":{"system":"sec-edgar","filing":"0001567619-18-007050","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1581720/000156761918007050/doc1.xml","form_type":"4"}},{"id":3750024,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":11096,"kind":"person","name":"Van Naarden Jacob","position":1,"cik":"0001661254","reported_name":"Van Naarden Jacob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2018-11-28T17:13:30.000Z","date":"2018-11-27","kind":"sale","acquired":false,"shares":1170,"price":138.83,"value":162431.1,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the aggregate of sales effected on the same day at different prices."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $138.52 to $139.18 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":16081,"source":{"system":"sec-edgar","filing":"0001567619-18-007050","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1581720/000156761918007050/doc1.xml","form_type":"4"}},{"id":3750023,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":11096,"kind":"person","name":"Van Naarden Jacob","position":1,"cik":"0001661254","reported_name":"Van Naarden Jacob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2018-11-28T17:13:30.000Z","date":"2018-11-27","kind":"sale","acquired":false,"shares":949,"price":138.08,"value":131037.92,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the aggregate of sales effected on the same day at different prices."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $137.52 to $138.48 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":17251,"source":{"system":"sec-edgar","filing":"0001567619-18-007050","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1581720/000156761918007050/doc1.xml","form_type":"4"}},{"id":3750022,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":11096,"kind":"person","name":"Van Naarden Jacob","position":1,"cik":"0001661254","reported_name":"Van Naarden Jacob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2018-11-28T17:13:30.000Z","date":"2018-11-27","kind":"exercise","acquired":true,"shares":2057,"price":13.67,"value":28119.19,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."}],"balance_after":18200,"source":{"system":"sec-edgar","filing":"0001567619-18-007050","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1581720/000156761918007050/doc1.xml","form_type":"4"}},{"id":3750021,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":11096,"kind":"person","name":"Van Naarden Jacob","position":1,"cik":"0001661254","reported_name":"Van Naarden Jacob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2018-11-28T17:13:30.000Z","date":"2018-11-27","kind":"exercise","acquired":true,"shares":2443,"price":3.648,"value":8912.064,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."}],"balance_after":16143,"source":{"system":"sec-edgar","filing":"0001567619-18-007050","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1581720/000156761918007050/doc1.xml","form_type":"4"}},{"id":3750020,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":11096,"kind":"person","name":"Van Naarden Jacob","position":1,"cik":"0001661254","reported_name":"Van Naarden Jacob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2018-11-28T17:13:30.000Z","date":"2018-11-26","kind":"sale","acquired":false,"shares":200,"price":156.45,"value":31290.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."}],"balance_after":13700,"source":{"system":"sec-edgar","filing":"0001567619-18-007050","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1581720/000156761918007050/doc1.xml","form_type":"4"}},{"id":3750019,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":11096,"kind":"person","name":"Van Naarden Jacob","position":1,"cik":"0001661254","reported_name":"Van Naarden Jacob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2018-11-28T17:13:30.000Z","date":"2018-11-26","kind":"sale","acquired":false,"shares":600,"price":155.3,"value":93180.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the aggregate of sales effected on the same day at different prices."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $155.04 to $155.44 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":13900,"source":{"system":"sec-edgar","filing":"0001567619-18-007050","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1581720/000156761918007050/doc1.xml","form_type":"4"}},{"id":3750018,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":11096,"kind":"person","name":"Van Naarden Jacob","position":1,"cik":"0001661254","reported_name":"Van Naarden Jacob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2018-11-28T17:13:30.000Z","date":"2018-11-26","kind":"sale","acquired":false,"shares":1500,"price":154,"value":231000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the aggregate of sales effected on the same day at different prices."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $153.75 to $154.69 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":14500,"source":{"system":"sec-edgar","filing":"0001567619-18-007050","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1581720/000156761918007050/doc1.xml","form_type":"4"}},{"id":3750017,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":11096,"kind":"person","name":"Van Naarden Jacob","position":1,"cik":"0001661254","reported_name":"Van Naarden Jacob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2018-11-28T17:13:30.000Z","date":"2018-11-26","kind":"sale","acquired":false,"shares":1644,"price":152.49,"value":250693.56,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the aggregate of sales effected on the same day at different prices."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $152.21 to $152.94 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":16000,"source":{"system":"sec-edgar","filing":"0001567619-18-007050","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1581720/000156761918007050/doc1.xml","form_type":"4"}},{"id":3750016,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":11096,"kind":"person","name":"Van Naarden Jacob","position":1,"cik":"0001661254","reported_name":"Van Naarden Jacob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2018-11-28T17:13:30.000Z","date":"2018-11-26","kind":"sale","acquired":false,"shares":1556,"price":151.71,"value":236060.76,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the aggregate of sales effected on the same day at different prices."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $151.19 to $152.14 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":17644,"source":{"system":"sec-edgar","filing":"0001567619-18-007050","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1581720/000156761918007050/doc1.xml","form_type":"4"}},{"id":3750015,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":11096,"kind":"person","name":"Van Naarden Jacob","position":1,"cik":"0001661254","reported_name":"Van Naarden Jacob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2018-11-28T17:13:30.000Z","date":"2018-11-26","kind":"exercise","acquired":true,"shares":5500,"price":3.648,"value":20064.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."}],"balance_after":19200,"source":{"system":"sec-edgar","filing":"0001567619-18-007050","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1581720/000156761918007050/doc1.xml","form_type":"4"}},{"id":3795770,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":11096,"kind":"person","name":"Van Naarden Jacob","position":1,"cik":"0001661254","reported_name":"Van Naarden Jacob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2018-10-05T16:46:07.000Z","date":"2001-10-04","kind":"exercise","acquired":false,"shares":4500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F13","text":"The stock option vested and became exercisable as to 25% of the shares subject to the option on May 12, 2015, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date."}],"balance_after":48269,"derivative":{"exercise_price":3.648,"expiration_date":"2024-06-18","underlying":"Common Stock","underlying_shares":4500},"source":{"system":"sec-edgar","filing":"0001567619-18-003762","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1581720/000156761918003762/doc1.xml","form_type":"4"}},{"id":3795769,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":11096,"kind":"person","name":"Van Naarden Jacob","position":1,"cik":"0001661254","reported_name":"Van Naarden Jacob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2018-10-05T16:46:07.000Z","date":"2018-10-03","kind":"exercise","acquired":false,"shares":5500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F13","text":"The stock option vested and became exercisable as to 25% of the shares subject to the option on May 12, 2015, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date."}],"balance_after":52769,"derivative":{"exercise_price":3.648,"expiration_date":"2024-06-18","underlying":"Common Stock","underlying_shares":5500},"source":{"system":"sec-edgar","filing":"0001567619-18-003762","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1581720/000156761918003762/doc1.xml","form_type":"4"}},{"id":3795768,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":11096,"kind":"person","name":"Van Naarden Jacob","position":1,"cik":"0001661254","reported_name":"Van Naarden Jacob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2018-10-05T16:46:07.000Z","date":"2018-10-04","kind":"sale","acquired":false,"shares":600,"price":164.6767,"value":98806.02,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the aggregate of sales effected on the same day at different prices."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $164.39 to $165.05 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":13700,"source":{"system":"sec-edgar","filing":"0001567619-18-003762","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1581720/000156761918003762/doc1.xml","form_type":"4"}},{"id":3795767,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":11096,"kind":"person","name":"Van Naarden Jacob","position":1,"cik":"0001661254","reported_name":"Van Naarden Jacob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2018-10-05T16:46:07.000Z","date":"2018-10-04","kind":"sale","acquired":false,"shares":1006,"price":163.7845,"value":164767.207,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the aggregate of sales effected on the same day at different prices."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $163.38 to $164.31 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":14300,"source":{"system":"sec-edgar","filing":"0001567619-18-003762","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1581720/000156761918003762/doc1.xml","form_type":"4"}},{"id":3795766,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":11096,"kind":"person","name":"Van Naarden Jacob","position":1,"cik":"0001661254","reported_name":"Van Naarden Jacob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2018-10-05T16:46:07.000Z","date":"2018-10-04","kind":"sale","acquired":false,"shares":1194,"price":162.701,"value":194264.994,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the aggregate of sales effected on the same day at different prices."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $162.22 to $163.21 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":15306,"source":{"system":"sec-edgar","filing":"0001567619-18-003762","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1581720/000156761918003762/doc1.xml","form_type":"4"}},{"id":3795765,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":11096,"kind":"person","name":"Van Naarden Jacob","position":1,"cik":"0001661254","reported_name":"Van Naarden Jacob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2018-10-05T16:46:07.000Z","date":"2018-10-04","kind":"sale","acquired":false,"shares":1100,"price":161.5205,"value":177672.55,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the aggregate of sales effected on the same day at different prices."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $161.22 to $162.13 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":16500,"source":{"system":"sec-edgar","filing":"0001567619-18-003762","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1581720/000156761918003762/doc1.xml","form_type":"4"}},{"id":3795764,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":11096,"kind":"person","name":"Van Naarden Jacob","position":1,"cik":"0001661254","reported_name":"Van Naarden Jacob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2018-10-05T16:46:07.000Z","date":"2018-10-04","kind":"sale","acquired":false,"shares":600,"price":160.6217,"value":96373.02,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the aggregate of sales effected on the same day at different prices."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $160.22 to $161.19 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":17600,"source":{"system":"sec-edgar","filing":"0001567619-18-003762","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1581720/000156761918003762/doc1.xml","form_type":"4"}},{"id":3795763,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":11096,"kind":"person","name":"Van Naarden Jacob","position":1,"cik":"0001661254","reported_name":"Van Naarden Jacob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2018-10-05T16:46:07.000Z","date":"2018-10-04","kind":"exercise","acquired":true,"shares":4500,"price":3.648,"value":16416.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."}],"balance_after":18200,"source":{"system":"sec-edgar","filing":"0001567619-18-003762","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1581720/000156761918003762/doc1.xml","form_type":"4"}},{"id":3795762,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":11096,"kind":"person","name":"Van Naarden Jacob","position":1,"cik":"0001661254","reported_name":"Van Naarden Jacob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2018-10-05T16:46:07.000Z","date":"2018-10-03","kind":"sale","acquired":false,"shares":300,"price":169.4,"value":50820.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the aggregate of sales effected on the same day at different prices."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $169.39 to $169.41 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":13700,"source":{"system":"sec-edgar","filing":"0001567619-18-003762","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1581720/000156761918003762/doc1.xml","form_type":"4"}},{"id":3795761,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":11096,"kind":"person","name":"Van Naarden Jacob","position":1,"cik":"0001661254","reported_name":"Van Naarden Jacob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2018-10-05T16:46:07.000Z","date":"2018-10-03","kind":"sale","acquired":false,"shares":2300,"price":168.8465,"value":388346.95,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the aggregate of sales effected on the same day at different prices."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $168.30 to $169.27 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":14000,"source":{"system":"sec-edgar","filing":"0001567619-18-003762","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1581720/000156761918003762/doc1.xml","form_type":"4"}},{"id":3795760,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":11096,"kind":"person","name":"Van Naarden Jacob","position":1,"cik":"0001661254","reported_name":"Van Naarden Jacob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2018-10-05T16:46:07.000Z","date":"2018-10-03","kind":"sale","acquired":false,"shares":500,"price":167.192,"value":83596.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the aggregate of sales effected on the same day at different prices."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $167.09 to $167.57 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":16300,"source":{"system":"sec-edgar","filing":"0001567619-18-003762","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1581720/000156761918003762/doc1.xml","form_type":"4"}},{"id":3795759,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":11096,"kind":"person","name":"Van Naarden Jacob","position":1,"cik":"0001661254","reported_name":"Van Naarden Jacob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2018-10-05T16:46:07.000Z","date":"2018-10-03","kind":"sale","acquired":false,"shares":400,"price":165.885,"value":66354.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the aggregate of sales effected on the same day at different prices."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $165.82 to $166.08 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":16800,"source":{"system":"sec-edgar","filing":"0001567619-18-003762","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1581720/000156761918003762/doc1.xml","form_type":"4"}},{"id":3795758,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":11096,"kind":"person","name":"Van Naarden Jacob","position":1,"cik":"0001661254","reported_name":"Van Naarden Jacob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2018-10-05T16:46:07.000Z","date":"2018-10-03","kind":"sale","acquired":false,"shares":2000,"price":165.1303,"value":330260.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the aggregate of sales effected on the same day at different prices."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $164.70 to $165.60 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":17200,"source":{"system":"sec-edgar","filing":"0001567619-18-003762","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1581720/000156761918003762/doc1.xml","form_type":"4"}},{"id":3795757,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":11096,"kind":"person","name":"Van Naarden Jacob","position":1,"cik":"0001661254","reported_name":"Van Naarden Jacob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2018-10-05T16:46:07.000Z","date":"2018-10-03","kind":"exercise","acquired":true,"shares":5500,"price":3.648,"value":20064.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."}],"balance_after":19200,"source":{"system":"sec-edgar","filing":"0001567619-18-003762","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1581720/000156761918003762/doc1.xml","form_type":"4"}},{"id":3815215,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":11096,"kind":"person","name":"Van Naarden Jacob","position":1,"cik":"0001661254","reported_name":"Van Naarden Jacob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2018-09-14T18:14:55.000Z","date":"2018-09-13","kind":"exercise","acquired":false,"shares":4500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"The stock option vested and became exercisable as to 25% of the shares subject to the option on May 12, 2015, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date."}],"balance_after":58269,"derivative":{"exercise_price":3.648,"expiration_date":"2024-06-18","underlying":"Common Stock","underlying_shares":4500},"source":{"system":"sec-edgar","filing":"0001567619-18-002676","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1581720/000156761918002676/doc1.xml","form_type":"4"}},{"id":3815214,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":11096,"kind":"person","name":"Van Naarden Jacob","position":1,"cik":"0001661254","reported_name":"Van Naarden Jacob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2018-09-14T18:14:55.000Z","date":"2018-09-12","kind":"exercise","acquired":false,"shares":5500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"The stock option vested and became exercisable as to 25% of the shares subject to the option on May 12, 2015, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date."}],"balance_after":62769,"derivative":{"exercise_price":3.648,"expiration_date":"2024-06-18","underlying":"Common Stock","underlying_shares":5500},"source":{"system":"sec-edgar","filing":"0001567619-18-002676","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1581720/000156761918002676/doc1.xml","form_type":"4"}},{"id":3815213,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":11096,"kind":"person","name":"Van Naarden Jacob","position":1,"cik":"0001661254","reported_name":"Van Naarden Jacob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2018-09-14T18:14:55.000Z","date":"2018-09-13","kind":"sale","acquired":false,"shares":300,"price":167.4867,"value":50246.01,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the aggregate of sales effected on the same day at different prices."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $167.37 to $168.3699 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":13700,"source":{"system":"sec-edgar","filing":"0001567619-18-002676","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1581720/000156761918002676/doc1.xml","form_type":"4"}},{"id":3815212,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":11096,"kind":"person","name":"Van Naarden Jacob","position":1,"cik":"0001661254","reported_name":"Van Naarden Jacob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2018-09-14T18:14:55.000Z","date":"2018-09-13","kind":"sale","acquired":false,"shares":1500,"price":166.6347,"value":249952.05,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the aggregate of sales effected on the same day at different prices."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $166.26 to $167.2599 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":14000,"source":{"system":"sec-edgar","filing":"0001567619-18-002676","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1581720/000156761918002676/doc1.xml","form_type":"4"}},{"id":3815211,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":11096,"kind":"person","name":"Van Naarden Jacob","position":1,"cik":"0001661254","reported_name":"Van Naarden Jacob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2018-09-14T18:14:55.000Z","date":"2018-09-13","kind":"sale","acquired":false,"shares":2700,"price":165.4463,"value":446705.01,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the aggregate of sales effected on the same day at different prices."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $165.04 to $166.0399 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":15500,"source":{"system":"sec-edgar","filing":"0001567619-18-002676","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1581720/000156761918002676/doc1.xml","form_type":"4"}},{"id":3815210,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":11096,"kind":"person","name":"Van Naarden Jacob","position":1,"cik":"0001661254","reported_name":"Van Naarden Jacob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2018-09-14T18:14:55.000Z","date":"2018-09-13","kind":"exercise","acquired":true,"shares":4500,"price":3.648,"value":16416.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."}],"balance_after":18200,"source":{"system":"sec-edgar","filing":"0001567619-18-002676","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1581720/000156761918002676/doc1.xml","form_type":"4"}},{"id":3815209,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":11096,"kind":"person","name":"Van Naarden Jacob","position":1,"cik":"0001661254","reported_name":"Van Naarden Jacob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2018-09-14T18:14:55.000Z","date":"2018-09-12","kind":"sale","acquired":false,"shares":600,"price":171.0267,"value":102616.02,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the aggregate of sales effected on the same day at different prices."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $170.75 to $171.7499 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":13700,"source":{"system":"sec-edgar","filing":"0001567619-18-002676","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1581720/000156761918002676/doc1.xml","form_type":"4"}},{"id":3815208,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":11096,"kind":"person","name":"Van Naarden Jacob","position":1,"cik":"0001661254","reported_name":"Van Naarden Jacob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2018-09-14T18:14:55.000Z","date":"2018-09-12","kind":"sale","acquired":false,"shares":200,"price":168.785,"value":33757.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the aggregate of sales effected on the same day at different prices."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $168.78 to $169.7799 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":14300,"source":{"system":"sec-edgar","filing":"0001567619-18-002676","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1581720/000156761918002676/doc1.xml","form_type":"4"}},{"id":3815207,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":11096,"kind":"person","name":"Van Naarden Jacob","position":1,"cik":"0001661254","reported_name":"Van Naarden Jacob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2018-09-14T18:14:55.000Z","date":"2018-09-12","kind":"sale","acquired":false,"shares":1000,"price":167.392,"value":167392.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the aggregate of sales effected on the same day at different prices."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $167.25 to $168.2499 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":14500,"source":{"system":"sec-edgar","filing":"0001567619-18-002676","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1581720/000156761918002676/doc1.xml","form_type":"4"}},{"id":3815206,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":11096,"kind":"person","name":"Van Naarden Jacob","position":1,"cik":"0001661254","reported_name":"Van Naarden Jacob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2018-09-14T18:14:55.000Z","date":"2018-09-12","kind":"sale","acquired":false,"shares":1059,"price":166.738,"value":176575.542,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the aggregate of sales effected on the same day at different prices."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $166.17 to $167.1699 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":15500,"source":{"system":"sec-edgar","filing":"0001567619-18-002676","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1581720/000156761918002676/doc1.xml","form_type":"4"}},{"id":3815205,"issuer":{"id":160155,"kind":"organization","name":"Loxo Oncology, Inc.","symbol":"LOXO"},"owners":[{"id":11096,"kind":"person","name":"Van Naarden Jacob","position":1,"cik":"0001661254","reported_name":"Van Naarden Jacob","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2018-09-14T18:14:55.000Z","date":"2018-09-12","kind":"sale","acquired":false,"shares":1885,"price":165.3156,"value":311619.906,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the aggregate of sales effected on the same day at different prices."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $164.94 to $165.9399 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":16559,"source":{"system":"sec-edgar","filing":"0001567619-18-002676","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1581720/000156761918002676/doc1.xml","form_type":"4"}}],"next_cursor":"2018-09-14T18:14:55.000000Z,3815205"}